title: [Muir-Torre syndrome. Diagnostic criteria and review of the literature].
abstract: We report on a 63-year-old female patient with Muir-Torre syndrome (MTS). In the course of this disease two carcinomas of the colon, a kerato-acanthoma and multiple sebaceous gland tumours, including four sebaceous carcinomas, appeared. This case is thought to be a hereditary form as one of daughters was also found to have a sebaceous epithelioma. MTS is a mostly autosomal-dominant disease with the association of sebaceous gland tumours and internal carcinomas. As the malignant tumours only show slight aggressiveness the prognosis is quite favourable. Oral isotretinoin therapy was successfully used for the inhibition of sebaceous gland proliferation. A narrower definition is presented and an updated survey of the published cases is given. Furthermore, the histopathologic peculiarities of sebaceous gland tumours, especially of sebaceous gland carcinomas, are discussed and compared to sebaceous gland tumours not connected with MTS. A total number of 100 of the 135 published cases of MTS were included and analysed regarding sebaceous gland tumours and other skin tumours. The data on internal carcinomas were taken from the work of Cohen et al. (1991) and 11 current cases were added.
authors.affiliation: Hautklinik, Minden.
authors.forename: C
authors.initials: C
authors.lastname: Hartig
authors.forename: W
authors.initials: W
authors.lastname: Stieler
authors.forename: R
authors.initials: R
authors.lastname: Stadler
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D006607:Adenoma, Sweat Gland / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D011125:Adenomatous Polyposis Coli / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D000284:Administration, Oral; D002277:Carcinoma / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D002869:Chromosome Aberrations / Q000235:genetics; D025063:Chromosome Disorders; D003937:Diagnosis, Differential; D005153:Facial Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D005260:Female; D005799:Genes, Dominant / Q000235:genetics; D006801:Humans; D015474:Isotretinoin / Q000627:therapeutic use; D007636:Keratoacanthoma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D009386:Neoplastic Syndromes, Hereditary / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D012626:Sebaceous Gland Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D013545:Sweat Glands / Q000473:pathology; D013577:Syndrome
chemical_list: D015474:Isotretinoin